All In MedTech

FDA Clearance Tracker · P170032-S019

Woven EndoBridge Aneurysm Embolization (WEB) System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Mar 20, 2026 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Mar 20, 2026

Approved

Time to decision

260 days

Received Jul 3, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P170032-S019
Device name
Woven EndoBridge Aneurysm Embolization (WEB) System
Applicant location
Aliso Viejo, CA
Received
Jul 3, 2025
Decided
Mar 20, 2026
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P170032

Device type

Device class
Class III

Every decision under product code OPR

FDA's approval statement

As written in FDA's record.

Approval of the revised protocol for the PAS1 PostMarket Surveillance-Long Term Safety post-approval study.

Source documents

Other decisions for MicroVention, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.